Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| Today 4:22 PM View:  | Burnett Patrick See Remarks | Arcutis Biotherapeutics, Inc. (ARQT) | Yesterday | Sale (Planned) | 9,555 | $8.74 | $83,489.70 | (4%) 269.3K to 259.75K | |
| Today 4:29 PM View: | Moore Matthew Richard SVP and Chief Business Officer | Arcutis Biotherapeutics, Inc. (ARQT) | Yesterday | Sale | 4,681 | $8.74 | $40,901.60 | (3%) 150.19K to 145.5K | |
| Today 4:22 PM View: | Watanabe Todd Franklin See Remarks Director | Arcutis Biotherapeutics, Inc. (ARQT) | Yesterday | Sale (Planned) | 13,783 | $8.74 | $120,433.00 | (1%) 1.11M to 1.09M | |
| Today 4:22 PM View: | Matsuda Masaru See Remark | Arcutis Biotherapeutics, Inc. (ARQT) | Yesterday | Sale (Planned) | 5,016 | $8.74 | $43,828.80 | (3%) 190.42K to 185.41K | |
| Today 4:29 PM View: | Moore Matthew Richard SVP and Chief Business Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 01-May-24 | Grant | 4,166 | -- | -- | 3% 146.02K to 150.19K | |
| 11-Apr-24 8:32 PM View: | Topper David Joseph Chief Financial Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 10-Apr-24 | Grant | 110,000 | -- | -- | 100% 0 to 110.0K | |
| 06-Mar-24 5:12 PM View: | Burnett Patrick See Remarks | Arcutis Biotherapeutics, Inc. (ARQT) | 04-Mar-24 | Sale (Planned) | 4,782 | $11.12 | $53,181.60 | (2%) 274.08K to 269.3K | |
| 06-Mar-24 5:09 PM View: | Watanabe Todd Franklin See Remarks Director | Arcutis Biotherapeutics, Inc. (ARQT) | 04-Mar-24 | Sale (Planned) | 14,903 | $11.12 | $165,739.00 | (1%) 1.12M to 1.11M | |
| 06-Mar-24 10:00 PM View: | Matsuda Masaru See Remark | Arcutis Biotherapeutics, Inc. (ARQT) | 04-Mar-24 | Sale (Planned) | 3,760 | $11.12 | $41,815.70 | (2%) 194.18K to 190.42K | |
| 06-Mar-24 4:28 PM View: | Heron Patrick J Director | Arcutis Biotherapeutics, Inc. (ARQT) | 04-Mar-24 | Private Purchase | 21,052 | $9.50 | $199,994.00 | < 1% 8.8M to 8.82M | |
| 06-Mar-24 10:00 PM View: | Moore Matthew Richard SVP and Chief Business Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 04-Mar-24 | Sale (Planned) | 3,468 | $11.12 | $38,568.30 | (2%) 149.49K to 146.02K | |
| 01-Mar-24 4:11 PM View: | Watanabe Todd Franklin See Remarks Director | Arcutis Biotherapeutics, Inc. (ARQT) | 28-Feb-24 | Sale (Planned) | 2,465 | $10.60 | $26,129.00 | (< 1%) 1.12M to 1.12M | |
| 15-Feb-24 6:23 PM View: | Smither John W Chief Financial Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 13-Feb-24 | Grant | 11,365 | -- | -- | 8% 141.39K to 152.76K | |
| 15-Feb-24 6:32 PM View: | Matsuda Masaru See Remark | Arcutis Biotherapeutics, Inc. (ARQT) | 13-Feb-24 | Grant | 119,550 | -- | -- | 160% 74.63K to 194.18K | |
| 15-Feb-24 6:47 PM View: | Moore Matthew Richard SVP and Chief Business Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 13-Feb-24 | Grant | 94,898 | -- | -- | 174% 54.59K to 149.49K | |
| 15-Feb-24 6:30 PM View: | Watanabe Todd Franklin See Remarks Director | Arcutis Biotherapeutics, Inc. (ARQT) | 13-Feb-24 | Grant | 264,882 | -- | -- | 31% 858.16K to 1.12M | |
| 15-Feb-24 6:36 PM View: | Burnett Patrick See Remarks | Arcutis Biotherapeutics, Inc. (ARQT) | 13-Feb-24 | Grant | 189,050 | -- | -- | 222% 85.03K to 274.08K | |
| 17-Jan-24 4:30 PM View: | Watanabe Todd Franklin See Remarks Director | Arcutis Biotherapeutics, Inc. (ARQT) | 12-Jan-24 | Grant | 125,000 | -- | -- | 25% 502.02K to 627.02K | |
| 17-Jan-24 4:35 PM View: | Burnett Patrick See Remarks | Arcutis Biotherapeutics, Inc. (ARQT) | 12-Jan-24 | Grant | 28,000 | -- | -- | 49% 57.03K to 85.03K | |
| 17-Jan-24 4:28 PM View: | Moore Matthew Richard SVP and Chief Business Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 12-Jan-24 | Grant | 28,000 | -- | -- | 105% 26.59K to 54.59K | |
| 17-Jan-24 4:34 PM View: | Edwards Larry Todd Chief Commercial Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 12-Jan-24 | Grant | 28,000 | -- | -- | 47% 60.0K to 88.0K | |
| 17-Jan-24 4:32 PM View: | Matsuda Masaru See Remark | Arcutis Biotherapeutics, Inc. (ARQT) | 12-Jan-24 | Grant | 28,000 | -- | -- | 60% 46.63K to 74.63K | |
| 03-Jan-24 5:30 PM View: | Burnett Patrick See Remarks | Arcutis Biotherapeutics, Inc. (ARQT) | 02-Jan-24 | Sale | 1,325 | $3.54 | $4,691.56 | (2%) 58.36K to 57.03K | |
| 22-Dec-23 5:24 PM View: | Watanabe Todd Franklin See Remarks Director | Arcutis Biotherapeutics, Inc. (ARQT) | 20-Dec-23 | Gift | 13,126 | -- | -- | 2% 550.85K to 563.97K | |
| 22-Dec-23 5:24 PM View: | Watanabe Todd Franklin See Remarks Director | Arcutis Biotherapeutics, Inc. (ARQT) | 20-Dec-23 | Gift | 13,126 | -- | -- | (2%) 563.97K to 550.85K | |
| 01-Dec-23 8:51 PM View: | Watanabe Todd Franklin See Remarks Director | Arcutis Biotherapeutics, Inc. (ARQT) | 01-Dec-23 | Option Exercise | 59,525 | $1.68 | $100,038.00 | 9% 672.17K to 731.7K | |
| 21-Nov-23 5:47 PM View: | Matsuda Masaru See Remark | Arcutis Biotherapeutics, Inc. (ARQT) | 21-Nov-23 | Sale | 1,850 | $1.98 | $3,661.15 | (4%) 48.48K to 46.63K | |
| 21-Nov-23 5:47 PM View: | Matsuda Masaru See Remark | Arcutis Biotherapeutics, Inc. (ARQT) | 18-Nov-23 | Grant | 4,875 | -- | -- | 11% 43.61K to 48.48K | |
| 26-Oct-23 4:09 PM View: | Frazier Life Sciences Viii,... 10% Owner | Arcutis Biotherapeutics, Inc. (ARQT) | 24-Oct-23 | Private Purchase | 80,000 | $2.50 | $200,000.00 | < 1% 8.75M to 8.83M | |
| 03-Oct-23 10:00 PM View: | Edwards Larry Todd Chief Commercial Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 27-Sep-23 | Grant | 60,000 | -- | -- | 100% 0 to 60.0K | |
| 22-Aug-23 12:24 PM View: | Burnett Patrick See Remarks | Arcutis Biotherapeutics, Inc. (ARQT) | 21-Aug-23 | Sale | 1,605 | $7.04 | $11,302.20 | (3%) 59.96K to 58.36K | |
| 02-Jun-23 7:10 PM View: | Curran Terrie Director | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Grant | 4,375 | -- | -- | 101% 4.31K to 8.69K | |
| 02-Jun-23 7:16 PM View: | Heron Patrick J Director 10% Owner | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Grant | 4,375 | -- | -- | 101% 4.31K to 8.69K | |
| 02-Jun-23 7:02 PM View: | Leonard Keith R Director | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Grant | 4,375 | -- | -- | 72% 6.06K to 10.44K | |
| 02-Jun-23 6:54 PM View: | Welgus Howard G. Director | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Grant | 4,375 | -- | -- | 2% 190.82K to 195.19K | |
| 01-Dec-23 8:51 PM View: | Watanabe Todd Franklin See Remarks Director | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Private Purchase | 1,463 | $6.38 | $9,333.94 | < 1% 731.7K to 733.16K | |
| 02-Jun-23 7:22 PM View: | Lin Sue-Jean Director | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Grant | 4,375 | -- | -- | 95% 4.61K to 8.99K | |
| 02-Jun-23 8:31 PM View: | Matsuda Masaru See Remark | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Grant | 1,463 | $6.38 | $9,333.94 | 3% 43.98K to 45.44K | |
| 02-Jun-23 7:13 PM View: | Chaudhuri Bhaskar Director | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Grant | 4,375 | -- | -- | < 1% 895.68K to 900.06K | |
| 02-Jun-23 7:08 PM View: | Gilbert Halley E Director | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Grant | 4,375 | -- | -- | 101% 4.31K to 8.69K | |
| 02-Jun-23 8:31 PM View: | Matsuda Masaru See Remark | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Sale | 1,830 | $7.80 | $14,278.20 | (4%) 45.44K to 43.61K | |
| 02-Jun-23 6:59 PM View: | Krishnamohan Neha Director | Arcutis Biotherapeutics, Inc. (ARQT) | 31-May-23 | Grant | 4,375 | -- | -- | 355% 1.23K to 5.61K | |
| 02-Jun-23 8:31 PM View: | Matsuda Masaru See Remark | Arcutis Biotherapeutics, Inc. (ARQT) | 27-May-23 | Grant | 4,875 | -- | -- | 12% 39.1K to 43.98K | |
| 18-Apr-23 7:00 PM View: | Welgus Howard G. Director | Arcutis Biotherapeutics, Inc. (ARQT) | 17-Apr-23 | Planned Option Sale | 8,500 | $13.97 | $118,728.00 | (4%) 199.32K to 190.82K | |
| 18-Apr-23 7:00 PM View: | Welgus Howard G. Director | Arcutis Biotherapeutics, Inc. (ARQT) | 17-Apr-23 | Option Exercise | 8,500 | $1.68 | $14,285.10 | 4% 190.82K to 199.32K | |
| 10-Apr-23 4:13 PM View: | Welgus Howard G. Director | Arcutis Biotherapeutics, Inc. (ARQT) | 06-Apr-23 | Planned Option Sale | 8,500 | $12.01 | $102,085.00 | (4%) 199.32K to 190.82K | |
| 10-Apr-23 4:13 PM View: | Welgus Howard G. Director | Arcutis Biotherapeutics, Inc. (ARQT) | 06-Apr-23 | Option Exercise | 8,500 | $1.68 | $14,285.10 | 4% 190.82K to 199.32K | |
| 08-Mar-23 4:26 PM View: | Osborne David W Chief Technical Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 06-Mar-23 | Sale (Planned) | 690 | $15.26 | $10,531.70 | (< 1%) 269.54K to 268.85K | |
| 08-Mar-23 4:26 PM View: | Turney Patricia A. SVP, Operations | Arcutis Biotherapeutics, Inc. (ARQT) | 06-Mar-23 | Sale (Planned) | 831 | $15.26 | $12,684.00 | (1%) 63.69K to 62.86K | |
| 08-Mar-23 4:25 PM View: | Lock Kenneth A. Chief Commercial Officer | Arcutis Biotherapeutics, Inc. (ARQT) | 06-Mar-23 | Sale (Planned) | 831 | $15.26 | $12,684.10 | (1%) 64.26K to 63.43K |
